IP Library Granted Patent US 7,737,282
Granted Patent B2
US 7,737,282 · App. 12/393,409 · Granted Jun 15, 2010

Benzimidazole compound crystal

Assignee: Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,737,282
App. No.
12/393,409
Granted
Jun 15, 2010
Kind
B2
Abstract

A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.

Claims (4)

1. An amorphous compound of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof.

2. A pharmaceutical composition comprising the amorphous compound according to claim 1 and a pharmaceutically acceptable excipient, carrier or diluent.

3. A pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition includes an effective amount of the amorphous compound to treat or prevent digestive ulcer.

4. A method for treating or preventing digestive ulcer, which comprises administering to a mammal in need thereof an effective amount of the amorphous compound of claim 1 .

Priority Claims (1)
JP 11-171509 · Jun 17, 1999 · national
Continuity (6)
Continuation 1200684500 · Jan 7, 2008
Continuation 1114990300 · Jun 10, 2005
Continuation 1065511400 · Sep 4, 2003
Continuation 1024332900 · Sep 13, 2002
Continuation 0967462400
Related Publication 20090163553A1 · Jun 25, 2009